Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
Por:
Kaski JP, Kammeraad JAE, Blom NA, Happonen JM, Janousek J, Klaassen S, Limongelli G, Östman-Smith I, Sarquella-Brugada G and Ziolkowska L
Publicada:
1 may 2023
Ahead of Print:
27 abr 2023
Resumen:
Sudden cardiac death is the most common mode of death during childhood and adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest risk is a major aspect of clinical care. The mainstay of preventative therapy is the implantable cardioverter-defibrillator, which has been shown to be effective at terminating malignant ventricular arrhythmias in children with hypertrophic cardiomyopathy but can be associated with substantial morbidity. Accurate identification of those children at highest risk who would benefit most from implantable cardioverter-defibrillator implantation while minimising the risk of complications is, therefore, essential. This position statement, on behalf of the Association for European Paediatric and Congenital Cardiology (AEPC), reviews the currently available data on established and proposed risk factors for sudden cardiac death in childhood-onset hypertrophic cardiomyopathy and current approaches for risk stratification in this population. It also provides guidance on identification of individuals at risk of sudden cardiac death and optimal management of implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Filiaciones:
Kaski JP:
Centre for Paediatric Inherited and Rare Cardiovascular Disease, University College London Institute of Cardiovascular Science, London, UK
Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, UK
Kammeraad JAE:
Erasmus MC - Sophia Children's Hospital, Department of Paediatric Cardiology, Rotterdam, the Netherlands
Blom NA:
Department of Pediatric Cardiology, University of Leiden, Leiden, the Netherlands
Amsterdam University Medical Centre, Amsterdam, the Netherlands
Happonen JM:
Department of Paediatric Cardiology, Helsinki University Children's Hospital, Helsinki, Finland
Janousek J:
Children's Heart Center, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
Klaassen S:
Department of Pediatric Cardiology, Charite-Universitatsmedizin Berlin, Berlin, Germany
Limongelli G:
Inherited and Rare Cardiovascular Disease Unit, AO dei Colli Monaldi Hospital, Universita della Campania "Luigi Vanvitelli", Naples, Italy
Östman-Smith I:
Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Sarquella-Brugada G:
Hospital Sant Joan de Déu, Barcelona, Spain
Ziolkowska L:
The Children's Memorial Health Institute, Warsaw, Poland
Green Submitted, hybrid
|